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There is an impelling demand to develop 
novel therapeutics against degenerative disorders. 
Approximately 30% of people over 80 years of age 
develop a dementia and 1-3% of those over 65 years have 
Parkinson’s disease. Over 17 million patients suffer from 
heart failure, mostly as a consequence of lack of cardiac 
regeneration after ischemic cardiomyocyte death. After 
75 years of age, 30% of individuals undergo age-related 
macular degeneration, a major cause of irreversible 
blindness, and 50% develop presbycusis.
All these degenerative conditions have at least three 
features in common: first, the function and structure of 
the affected tissues deteriorate over time; second, the 
functional cells in these organs (cardiomyocytes, neurons, 
retinal cells, neuroepithelial cells of the inner ear) are 
incapable of significant regeneration in adult life; third, 
there are no effective therapies slowing the progressive 
loss of these cells and, even less, promoting their 
regeneration. 
Despite the lack of curative therapies, notable 
progress has been achieved in understanding the cellular 
and molecular mechanisms leading to tissue degeneration. 
Thus, there is hope that novel biological therapeutics, 
able to specifically interfere with the different molecular 
mechanisms of disease onset and progression, might 
offer therapeutic opportunities. How to identify these 
therapeutics, however, remains a formidable challenge.
The screening of genetic libraries for a given 
function directly in vivo (thus moving from biochemical or 
phenotypic selection in vitro towards functional selection 
in vivo) would represent an exceptional asset for the 
identification of novel therapeutic factors, in the absence 
of any a priori, possibly biased, information on their 
molecular function. In contrast to phenotypic selection, 
however, functional screening of genetic libraries for 
degenerative conditions is still in its infancy, especially 
due to the intrinsic difficulty of delivering genes to post-
mitotic tissues. 
Indeed, functional selection in vivo demands a gene 
delivery vector that i) can be produced at very high titers; 
ii) infects resting or post-mitotic cells very efficiently, and 
iii) persists in these cells for prolonged periods of time 
in the absence of significant transgene silencing. Vectors 
based on the Adeno-Associated Virus (AAV) appear to suit 
all these requirements. These are relatively small vectors 
(viral capsid ~20 nm, genome size < 5 kb) that transduce 
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Figure 1: Outline of the AAV-based in vivo functional selection procedure (FunSel) for the identification of novel 
biological therapeutics for degenerative disorders. Cf. text for description.
Oncotarget26557www.impactjournals.com/oncotarget
post-mitotic cells in vivo at high efficiency, such as heart, 
brain and retina, and drive persistent transgene expression 
in these organs [1].
Our recent work [2] reports on the development of 
an innovative procedure for in vivo functional selection, 
which we named FunSel, in which arrayed AAV vector 
gene collections are used to iteratively transduce a given 
tissue to find potential therapeutic leads. A pool of AAV 
vectors, each one coding for a specific factor, is injected 
in vivo to transduce permissive cells (e.g. cardiomyocytes, 
skeletal muscle fibers, retinal cells, pancreas β-cells); each 
vector enters a different cell. After a few weeks, a selective 
stimulus is applied (e.g. coronary or femoral artery 
ligation, or chemical induction of cell death). Then, vector 
cDNA inserts are recovered and used to generate a new 
AAV preparation, which is submitted to additional cycles 
of selection. This iterative procedure leads to the selection 
of viral transgenes exerting a protective or regenerative 
effect on the expressing tissues (Figure 1). 
To provide proof-of-principle evidence of FunSel 
efficacy, we screened 100 factors from the murine 
secretome (including various cytokines, growth factors, 
hormones and extracellular matrix proteins) for their 
capacity to protect skeletal muscle and heart against acute 
ischemia. Using the analysed set of genes, FunSel led to 
the identification of ghrelin as a powerful myoprotective 
factor. Ghrelin is a 28-amino acid circulating hormone, 
physiologically produced by the stomach in conditions of 
starvation, and exerting a powerful secretagogue function 
eventually leading to the release of growth hormone from 
the pituitary [3]. Indeed we found that both the major 
circulating form of the peptide, which is octanoylated on 
serine 3 [4], and the unmodified peptide expressed from 
our AAV vectors, protect both skeletal muscle fibers and 
cardiomyocytes from ischemic cell death and preserve 
cardiac function over time.
Why was ghrelin selected by our functional 
screening? In principle, the tissue protective functions 
selected by FunSel could ensue from different molecular 
mechanisms, including inhibition of apoptosis, induction 
of neovascularization, protection from inflammation or 
immune response, among others. We found that a major 
function of ghrelin was to inhibit apoptosis through the 
induction of autophagy, a process exerting a fundamental 
role in both normal homeostasis and after tissue insult. In 
particular, autophagy specifically protects from ischemic 
damage by removing dysfunctional organelles through 
the lysosomal degradative pathway [5]. Under stressful 
conditions, particularly in the heart [6], autophagy is 
induced as an adaptive response to avoid cell death.
In principle, FunSel can be applied using arrayed 
genetic collections encoding for any kind of proteins, 
ranging from transcription factors to membrane receptors. 
The use of genetic libraries encoding for genes from 
the secretome (approximately 2,000 genes [7]) offers 
the important advantage of permitting the identification 
of factors that could eventually exert their therapeutic 
function once administered as recombinant proteins. This 
appears to be an important step towards the generation of 
new injectable, biological drugs targeting degenerative 
conditions.
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